Curated news and analysis on clinical trials, drug approvals, and medical research.
GC Biopharma said a review paper in Human Vaccines & Therapeutics analyzed more than 40 studies on its MAV/06 varicella vaccine strain. The paper summarized 30 years of data showing 99-100% neutralizing antibody rates and adverse event incidence of 0.41 to 0.57 cases per 100,000 doses.
Athletes at the Milano Cortina 2026 Olympic Winter Games span a wide age range, from teenagers to competitors in their 50s. Research suggests hormonal changes may affect bone health and stress-fracture risk more directly than athletic performance.
New data from 1,868 SEER-linked patients showed DecisionDx-Melanoma identified significant five-year survival differences within the same AJCC stage. The findings were presented at the 2026 AAD Annual Meeting.
A meta-analysis of 68 studies found patients with mental disorders consistently showed higher brain age than healthy controls. The largest effects were seen in schizophrenia spectrum and neurocognitive disorders.
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
JAMA Neurology published Phase 2b PARADIGM results for PrimeC in ALS, showing slower functional decline, fewer ALS-related complications and longer survival. NeuroSense is preparing a Phase 3 trial and received Brazilian patent protection through October 2042.
The microfluidics market is projected to grow from $10.33 billion in 2025 to $20.73 billion by 2030. Growth is tied to lab-on-a-chip research, miniaturized diagnostics, and pharmaceutical R&D adoption.
Organogenesis Holdings said first-quarter fiscal 2026 financial results will be reported after the market closes on May 7, followed by a 5:00 p.m. Eastern Time conference call.
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
NRx Pharmaceuticals said an FDA Type C meeting indicated a path to an NDA for NRX-100, using clinical trial results and real-world ketamine data from more than 65,000 patients.
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
Agios Pharmaceuticals said it will host a conference call and live webcast on April 29, 2026, at 8:00 a.m. ET to report first-quarter 2026 financial results and business highlights. The webcast and replay will be available on the Investors section of the company’s website.
Scinai acquired Recipharm Israel Ltd., added the Yavne cGMP manufacturing site to its CDMO platform, and entered a long-term commercial collaboration with Recipharm. The company later reorganized its CDMO activities into Scinai Biopharma Services and outlined a 2026 CDMO revenue target of about $5 million.
NRx said the FDA outlined a path for a New Drug Application for NRX-100, a preservative-free ketamine formulation for depression with suicidality. The company plans to submit the NDA by June 2026 and said no additional nonclinical or bridging studies would be required.
Dangerous nicotine exposures from vapes in U.S. children under 6 soared 243% from 2016 to 2023, while exposures from cigarettes and other traditional tobacco products fell 43%. The study, based on more than 92,000 poison control reports, said many recent cases involved children actively using e-cigarette devices.
A study found that pregnancy exposure to the fungicide vinclozolin triggered disease patterns in rats that persisted for 20 generations. The findings point to epigenetic changes in germline cells and potential uses for epigenetic biomarkers in preventative diagnostics.
Two Nature Chemical Biology studies described new routes to molecular glue discovery. One identified ZZ1 and YPEL5-linked CTLH recruitment, while another found an ENL degrader in leukemia cells.
A single-arm trial in Nature Medicine found that a one-time OTOF gene therapy injection improved hearing in all 10 patients with congenital deafness. Some responded within a month, and no serious adverse events were observed.
Phase 3 PSMAddition showed that adding 177Lu-PSMA-617 to ADT plus an ARPI improved radiographic progression-free survival in PSMA-positive mHSPC. Health-related quality of life and pain were largely maintained.
Blackstone closed its sixth dedicated life sciences fund at a $6.3 billion hard cap, the largest private fund raised for the sector. The vehicle is nearly 40% larger than its 2020 predecessor and targets late-stage drug assets.
